- Home
- KPLT vs XGN Comparison
KPLT vs XGN Comparison
Compare KPLT & XGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KPLT | XGN |
|---|---|---|
| Founded | 2012 | 2002 |
| Country | United States | United States |
| Employees | 94 | N/A |
| Industry | Diversified Commercial Services | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.7M | 110.7M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | KPLT | XGN |
|---|---|---|
| Price | $6.69 | $4.58 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | ★ $10.00 | $8.86 |
| AVG Volume (30 Days) | 13.2K | ★ 296.3K |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $18.62 | $8.12 |
| Revenue Next Year | $15.34 | $13.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.50 | $2.59 |
| 52 Week High | $24.15 | $12.23 |
Technical Indicators
Market Signals| Indicator | KPLT | XGN |
|---|---|---|
| Relative Strength Index (RSI) | 57.91 | 55.13 |
| Support Level | $6.55 | $4.11 |
| Resistance Level | $6.79 | $4.85 |
| Average True Range (ATR) | 0.36 | 0.34 |
| MACD | 0.06 | -0.04 |
| Stochastic Oscillator | 85.99 | 52.22 |
Price Performance
Historical ComparisonAbout KPLT Katapult Holdings Inc.
Katapult Holdings Inc. is a technology-driven lease-to-own platform that integrates with omni-channel retailers and e-commerce platforms to power the purchase of everyday durable goods for underserved U.S. non-prime consumers. It is an e-commerce-focused FinTech company offering a lease-purchase solution to consumers and enabling essential transactions at the merchant point of sale. Katapult is associated with hundreds of retailers across the United States.
About XGN Exagen Inc.
Exagen Inc is a medical technology company focused on the design, development and commercialization of diagnostic testing products under its AVISE brand. These products are used for the differential diagnosis, prognosis, and monitoring of rheumatic, autoimmune, and related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company operates in one operating segment. The majority of the company's revenue is derived from sales of its testing products.